Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label firategrast study of cerebrospinal fluid and blood leukocyte counts in relapsing multiple sclerosis
2006-007057-42Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of firategrast in multiple sclerosis (MS), sponsored by GSK. Primary endpoints: Number and change in total leukocytes in cerebrospinal fluid and blood, Number and change in total lymphocytes in cerebrospinal fluid and blood and 5 more. Started Feb 2007; status: completed.
02
Drugs
firategrast
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-007057-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007057-42.